Alzamend Neuro, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALZN Nasdaq 2836 www.alzamend.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alzamend Neuro, Inc.

Alzamend Neuro to Present at the Sequire Investor Summit - Jan 15th, 2025 1:00 pm
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo - Dec 18th, 2024 1:00 pm
Alzamend Neuro says net cash gained by financing activity $8.3M - Dec 13th, 2024 1:15 pm
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs - Dec 12th, 2024 1:00 pm
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Nov 19th, 2024 1:00 pm
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Nov 19th, 2024 12:30 pm
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - Oct 16th, 2024 12:00 pm
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Oct 16th, 2024 11:30 am
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - Oct 15th, 2024 12:00 pm
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Oct 10th, 2024 12:00 pm
Alzamend Neuro Issues Letter to Stockholders - Aug 26th, 2024 12:00 pm
Top Midday Gainers - Aug 19th, 2024 6:02 pm
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Aug 19th, 2024 12:00 pm
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder - Aug 12th, 2024 12:00 pm
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder - Aug 6th, 2024 12:00 pm
Alzamend Neuro partners with Mass General for Alzheimer’s treatment trial - Aug 6th, 2024 9:32 am
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study - Aug 5th, 2024 11:30 am
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - Jul 31st, 2024 12:00 pm
Alzamend Neuro Announces Reverse Stock Split - Jul 12th, 2024 12:00 pm
Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel - May 22nd, 2024 12:00 pm